Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Jurnal Insan Farmasi Indonesia Media Farmasi Indonesia
Maya Octasari, Paulina
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemistry Immunology & microbiology Medicine & Pharmacology Physics Other

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
POTENSI ANTIDIABETIK EKSTRAK ETANOLIK BIJI SALAK (Salacca zalacca) PADA MENCIT PUTIH JANTAN GALUR SWISS (Mus musculus) YANG DIINDUKSI ALOKSAN Rukminingsih, Fef; Maya Octasari, Paulina; Kristi Nadila, Lilis; Aulia Putri, Fayza
Jurnal Insan Farmasi Indonesia Vol 6 No 2 (2023): Jurnal Insan Farmasi Indonesia
Publisher : Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36387/jifi.v6i2.1600

Abstract

Traditional medicine is an alternative treatment for diabetes mellitus. Flavonoids are compounds that have the activity of lowering blood glucose levels. Snake fruit (Salacca zalacca) contains flavonoids. This study aims to determine the antidiabetic potential of snake fruit ethanolic extract (SFEE) on male white Swiss mice. This research is an experimental study that consisted of 2 stages, namely testing the antidiabetic power and testing the hypoglycemia side effects of SFEE. Each stage was tested on 5 treatment groups. The various doses used were 91 mg, 114 mg, and 137 mg of 20g mice. In stage 1, fasting blood sugar checks are carried out on days 0, 3 and 17. Meanwhile, in stage 2, fasting blood sugar checks are carried out on days 1, 7 and 14. The positive control in the stage 1 test was metformin, while the stage 2 test used glibenclamide. The results showed that varying doses of SFEE  91 mg, 114 mg, and 137 mg of 20g mice had antidiabetic power of 62.87%, 68.07%, and 70.98%. The greater the dose of SFEE, the greater its antidiabetic power. However, the larger the dose of SFEE and the longer it is administered, the hypoglycemic effects will occur
PENGGUNAAN ANTIHIPERTENSI PADA PASIEN STROKE NON HEMORAGIK DI INSTALASI FARMASI RAWAT JALAN RUMAH SAKIT X SEMARANG Maya OCTASARI, Paulina; Veny OKTAVIANI, Anastasia
Media Farmasi Indonesia Vol. 15 No. 2 (2020): Media Farmasi Indonesia
Publisher : SEKOLAH TINGGI ILMU FARMASI YAYASAN PHARMASI SEMARANG

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (448.286 KB) | DOI: 10.53359/mfi.v15i2.161

Abstract

Non-hemorrhagic stroke is a functional disorder of the brain’s neurologic deficits caused by vasocontraction due to blockage in the arterial vessel leading to the brain. There were 79% of non-hemorrhagic stroke patients are caused by hypertension. Antihypertensive therapy for the patients given as secondary therapy to prevent recurrent stroke, decreased brain edema risk, hemorrhagic risk, and prevent further vascular damage. Therefore this research aimed to evaluate antihypertensive usage in non-hemorrhagic stroke patients in the Hospital. The research is an observational descriptive with cross-sectional design and retrospective data. Data retrieval through the medical record of outpatients with ages 36-65 years were diagnosed with non-hemorrhagic stroke with or without comorbidities and National Health Insurance patients period of October - December in 2019. Data were classified based on age, gender, and antihypertensive agent, and were analyzed by calculating the percentage of patients who have decrease, stability, and increased blood pressure. 92 patients who were included in the inclusion criteria. The result showed that more male patients (68,48%), mostly age category 55-65 years (70,65%) with hypertensive (51,09%). Antihypertensive usage in non-hemorrhagic stroke is mostly used CCB group (70,65%). The percentage of patients who suffered a decrease in systolic blood pressure as much as 53 patients (57,6%), meanwhile the decrease in diastolic blood pressure as much as 63 patients (68,46%). There were 69 patients (75%) has blood pressure target therapy.
Co-Authors Aulia Putri, Fayza Kristi Nadila, Lilis Rukminingsih, Fef Veny OKTAVIANI, Anastasia